Aptose Biosciences (NASDAQ:APTO) Posts Earnings Results

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03, Morningstar.com reports.

NASDAQ APTO opened at $2.00 on Friday. Aptose Biosciences has a twelve month low of $1.57 and a twelve month high of $4.55. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.09. The stock has a market cap of $98.47 million, a price-to-earnings ratio of -2.33 and a beta of 1.57.

In related news, Director Erich Platzer sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Gregory K. Chow bought 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was acquired at an average cost of $1.75 per share, for a total transaction of $26,250.00. Following the completion of the purchase, the chief financial officer now directly owns 122,014 shares of the company’s stock, valued at $213,524.50. The disclosure for this purchase can be found here. Insiders have acquired 35,000 shares of company stock worth $63,750 in the last 90 days. Company insiders own 7.34% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in shares of Aptose Biosciences in the first quarter worth about $35,000. Patriot Financial Group Insurance Agency LLC boosted its position in Aptose Biosciences by 37.3% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 78,829 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 21,400 shares in the last quarter. Boston Advisors LLC bought a new stake in Aptose Biosciences during the 1st quarter valued at approximately $36,000. Virtu Financial LLC bought a new stake in Aptose Biosciences during the 1st quarter valued at approximately $198,000. Finally, Geode Capital Management LLC bought a new stake in Aptose Biosciences during the 4th quarter valued at approximately $33,000. 7.93% of the stock is currently owned by institutional investors.

Several research firms have recently issued reports on APTO. HC Wainwright set a $9.00 target price on Aptose Biosciences and gave the company a “buy” rating in a report on Friday, March 22nd. Zacks Investment Research lowered Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, March 26th. Roth Capital restated a “buy” rating on shares of Aptose Biosciences in a research report on Thursday, May 23rd. Finally, Royal Bank of Canada initiated coverage on Aptose Biosciences in a research report on Friday, March 1st. They set an “outperform” rating and a $6.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $5.75.

ILLEGAL ACTIVITY WARNING: This article was posted by Rockland Register and is owned by of Rockland Register. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://rocklandregister.com/2019/05/31/aptose-biosciences-apto-posts-quarterly-earnings-results-beats-expectations-by-0-03-eps.html.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Recommended Story: Lock-Up Period Expiration

Earnings History for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.